CA2846187A1 - Pyrimido-pyridazinone compounds and use thereof - Google Patents
Pyrimido-pyridazinone compounds and use thereof Download PDFInfo
- Publication number
- CA2846187A1 CA2846187A1 CA2846187A CA2846187A CA2846187A1 CA 2846187 A1 CA2846187 A1 CA 2846187A1 CA 2846187 A CA2846187 A CA 2846187A CA 2846187 A CA2846187 A CA 2846187A CA 2846187 A1 CA2846187 A1 CA 2846187A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridazin
- amino
- phenyl
- oxo
- dihydropyrimido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161526525P | 2011-08-23 | 2011-08-23 | |
| US61/526,525 | 2011-08-23 | ||
| PCT/US2012/051980 WO2013028818A1 (en) | 2011-08-23 | 2012-08-23 | Pyrimido- pyridazinone compounds and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2846187A1 true CA2846187A1 (en) | 2013-02-28 |
Family
ID=46829884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2846187A Pending CA2846187A1 (en) | 2011-08-23 | 2012-08-23 | Pyrimido-pyridazinone compounds and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US8729079B2 (enExample) |
| EP (4) | EP3392252B1 (enExample) |
| JP (1) | JP5993010B2 (enExample) |
| CN (2) | CN108707151B (enExample) |
| BR (1) | BR112014003981A2 (enExample) |
| CA (1) | CA2846187A1 (enExample) |
| DK (2) | DK2748166T3 (enExample) |
| ES (2) | ES2969977T3 (enExample) |
| FI (1) | FI3392252T3 (enExample) |
| HU (1) | HUE065564T2 (enExample) |
| IL (1) | IL231082A (enExample) |
| MX (1) | MX361458B (enExample) |
| PL (1) | PL2748166T3 (enExample) |
| WO (1) | WO2013028818A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014003981A2 (pt) * | 2011-08-23 | 2017-03-07 | Endo Pharmaceuticals Inc | compostos de pirimido-piridazinona e seu uso |
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| WO2018187294A1 (en) * | 2017-04-03 | 2018-10-11 | Asana Biosciences, Llc | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof |
| CN110809471A (zh) | 2017-04-28 | 2020-02-18 | 阿沙纳生物科学公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
| CN111961035B (zh) * | 2019-05-20 | 2022-11-01 | 南京科技职业学院 | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 |
| CN114174298B (zh) * | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN113583026B (zh) * | 2020-04-30 | 2024-06-14 | 杭州英创医药科技有限公司 | 一类含有稠合三环结构的化合物 |
| CN115916747A (zh) * | 2020-07-01 | 2023-04-04 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| AU2022421224A1 (en) * | 2021-12-22 | 2024-06-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| US20250171448A1 (en) | 2022-02-23 | 2025-05-29 | Teva Pharmaceuticals International Gmbh | Solid state forms of gusacitinib |
| WO2023192989A2 (en) * | 2022-04-01 | 2023-10-05 | Azkarra Therapeutics, Inc. | Phthalazinone compounds as parp7 inhibitors |
| WO2025020171A1 (en) * | 2023-07-27 | 2025-01-30 | Libertas Bio, Inc. | Crystalline forms of a jak/syk inhibitor |
| IL326153A (en) | 2023-07-27 | 2026-03-01 | Libertas Bio Inc | Solid state forms of GUSACITINIB |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE756508A (fr) | 1969-09-24 | 1971-03-01 | Takeda Chemical Industries Ltd | Derives de pyrimidopyridazine |
| CA1004223A (en) * | 1972-05-12 | 1977-01-25 | Theodor Denzel | Amino derivatives of pyrido(2,3-d)pyridazine carboxylic acids and esters |
| JPS4948695U (enExample) | 1972-07-29 | 1974-04-27 | ||
| JPS50101387A (enExample) * | 1974-01-16 | 1975-08-11 | ||
| CA1052046A (en) | 1974-01-21 | 1979-04-03 | American Cyanamid Company | Unsymmetrically substituted 1,4-dioxane-2,5-diones |
| US5369086A (en) | 1993-04-28 | 1994-11-29 | Zeneca Limited | N-benzotriazoles |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| JPH0948695A (ja) | 1995-08-02 | 1997-02-18 | Toshiba Ceramics Co Ltd | シリコン単結晶の製造方法 |
| JP2002504550A (ja) | 1998-02-25 | 2002-02-12 | ファルマシア・アンド・アップジョン・カンパニー | 抗微生物剤として有用な置換アミノメチルイソオキサゾリン誘導体 |
| ID28376A (id) | 1998-11-10 | 2001-05-17 | Janssen Pharmaceutica Nv | Pirimidina yang menghambat replikasi hiv |
| JP4977940B2 (ja) * | 2000-09-22 | 2012-07-18 | エム・エス・ディー・オス・ベー・フェー | 二環式ヘテロ芳香族化合物 |
| CA2446514A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) |
| WO2003075828A2 (en) | 2002-03-11 | 2003-09-18 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
| IL166241A0 (en) | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| US20040242568A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| US8575342B2 (en) | 2004-09-30 | 2013-11-05 | Tibotech Pharmaceuticals Ltd. | HIV inhibiting 5-heterocyclyl pyrimidines |
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| CN101189234B (zh) | 2005-03-25 | 2011-08-17 | 泰博特克药品有限公司 | Hcv的杂二环抑制剂 |
| BRPI0609650A2 (pt) | 2005-03-25 | 2010-04-20 | Tibotec Pharm Ltd | inibidores heterobicìlicos de hvc |
| EP1874304B1 (en) | 2005-04-29 | 2009-07-15 | Janssen Pharmaceutica N.V. | Benzotriazole derivatives as cannabinoid receptor antagonists |
| WO2007063934A1 (ja) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | 脂環式複素環化合物 |
| WO2007082131A1 (en) | 2006-01-09 | 2007-07-19 | Bristol-Myers Squibb Company | Process for the preparation of hydroxy substituted heterocycles |
| WO2007125405A2 (en) | 2006-05-01 | 2007-11-08 | Pfizer Products Inc. | Substituted 2-amino-fused heterocyclic compounds |
| GB0625196D0 (en) | 2006-12-18 | 2007-01-24 | 7Tm Pharma As | Modulators of cannabinoid receptor |
| MX347085B (es) * | 2006-12-28 | 2017-04-06 | Abbott Laboratories * | Inhibidores de la poli (adp-ribosa) polimerasa. |
| BRPI0808772A2 (pt) | 2007-03-14 | 2014-08-12 | Exelixis Inc | Inibidores da via de hedgehog |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP2012504157A (ja) * | 2008-09-30 | 2012-02-16 | アストラゼネカ アクチボラグ | 複素環式ｊａｋキナーゼ阻害剤 |
| TW201016676A (en) | 2008-10-03 | 2010-05-01 | Astrazeneca Ab | Heterocyclic derivatives and methods of use thereof |
| EA022417B1 (ru) | 2008-10-21 | 2015-12-30 | Саймабэй Терапевтикс, Инк. | Арильные агонисты рецептора gpr120 и их применение |
| JP5993742B2 (ja) * | 2009-10-29 | 2016-09-14 | ジェノスコ | キナーゼ阻害剤 |
| TW201130852A (en) * | 2009-12-23 | 2011-09-16 | Abbott Lab | Novel thienopyrrole compounds |
| US8440662B2 (en) | 2010-10-31 | 2013-05-14 | Endo Pharmaceuticals, Inc. | Substituted quinazoline and pyrido-pyrimidine derivatives |
| BR112014003981A2 (pt) * | 2011-08-23 | 2017-03-07 | Endo Pharmaceuticals Inc | compostos de pirimido-piridazinona e seu uso |
| US9145411B2 (en) | 2012-08-02 | 2015-09-29 | Asana Biosciences, Llc | Substituted amino-pyrimidine derivatives |
| AR106830A1 (es) * | 2015-12-04 | 2018-02-21 | Asana Biosciences Llc | Usos de piridazinonas para tratar el cáncer |
| CN110809471A (zh) * | 2017-04-28 | 2020-02-18 | 阿沙纳生物科学公司 | 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型 |
-
2012
- 2012-08-23 BR BR112014003981A patent/BR112014003981A2/pt not_active IP Right Cessation
- 2012-08-23 JP JP2014527282A patent/JP5993010B2/ja active Active
- 2012-08-23 PL PL12756865T patent/PL2748166T3/pl unknown
- 2012-08-23 EP EP18175788.1A patent/EP3392252B1/en active Active
- 2012-08-23 US US13/592,511 patent/US8729079B2/en active Active
- 2012-08-23 CA CA2846187A patent/CA2846187A1/en active Pending
- 2012-08-23 MX MX2014002112A patent/MX361458B/es active IP Right Grant
- 2012-08-23 DK DK12756865.7T patent/DK2748166T3/en active
- 2012-08-23 DK DK18175788.1T patent/DK3392252T3/da active
- 2012-08-23 ES ES18175788T patent/ES2969977T3/es active Active
- 2012-08-23 CN CN201810492306.1A patent/CN108707151B/zh active Active
- 2012-08-23 ES ES12756865T patent/ES2690971T3/es active Active
- 2012-08-23 CN CN201280051788.8A patent/CN103974955B/zh active Active
- 2012-08-23 EP EP18182723.9A patent/EP3404029A3/en not_active Withdrawn
- 2012-08-23 HU HUE18175788A patent/HUE065564T2/hu unknown
- 2012-08-23 EP EP23201319.3A patent/EP4327886A3/en active Pending
- 2012-08-23 WO PCT/US2012/051980 patent/WO2013028818A1/en not_active Ceased
- 2012-08-23 FI FIEP18175788.1T patent/FI3392252T3/fi active
- 2012-08-23 EP EP12756865.7A patent/EP2748166B1/en active Active
-
2014
- 2014-02-23 IL IL231082A patent/IL231082A/en active IP Right Grant
- 2014-04-03 US US14/244,183 patent/US9382277B2/en active Active
-
2016
- 2016-04-25 US US15/137,950 patent/US10183944B2/en active Active
-
2018
- 2018-11-30 US US16/206,395 patent/US10647720B2/en active Active
-
2020
- 2020-02-25 US US16/800,111 patent/US20200190095A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10647720B2 (en) | Pyrimido-pyridazinone compounds and methods of use thereof | |
| AU2022211789B2 (en) | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component | |
| AU2016252404B2 (en) | Novel compounds | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| CA3198885A1 (en) | Azaquinazoline pan-kras inhibitors | |
| TWI719209B (zh) | 嘧啶酪氨酸激酶抑制劑 | |
| TWI818538B (zh) | Ｌｐａ受體拮抗劑及其用途 | |
| CA3020792A1 (en) | Conjugates comprising ripk2 inhibitors | |
| JP2019537588A (ja) | 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物 | |
| JP2022526295A (ja) | キノリンおよびキナゾリン化合物およびその使用方法 | |
| CA3193325A1 (en) | Alpha protein kinase 1 inhibitors and methods of use | |
| US9000185B2 (en) | Cycloalkyl ether compounds and their use as BACE inhibitors | |
| WO2018187294A1 (en) | Pyrimido-pyridazinone compound combinations, methods, kits and formulations thereof | |
| FR2986232A1 (fr) | Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique | |
| US12421229B2 (en) | Hydropyrido[1,2-α]pyrazine compounds for the treatment of autoimmune disease | |
| CN111961035A (zh) | 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用 | |
| HK40107186A (en) | Pyrimido- pyridazinone compounds and use thereof | |
| HK1262920A1 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| HK1262920B (en) | Pyrimido- pyridazinone compounds and use thereof | |
| CA3200710A1 (en) | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | |
| HK40000773A (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| NZ623858A (en) | 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives | |
| HK1209284B (en) | Pyrimidinyl tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170810 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20220729 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20220729 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20220729 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20220729 |
|
| FZDC | Discontinued application reinstated |
Effective date: 20220729 |